Manual physiotherapy to rats included gentle flexing and extending the limb and housing animals in a wire-mesh floor cage for about 8 h a day
Frequently Asked Questions Is FOXO4-DRI sold for human use
Some research suggests that the glucagon component may have muscle-sparing properties compared to pure GLP-1 agonists, but this requires further study
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
Treatments comprised 1 M oligomycin (Sigma-Aldrich, 75351), 1.5 M FCCP (Sigma-Aldrich, C2920) and 100 nM rotenone (Sigma-Aldrich, R8875) plus 1 M antimycin A (Sigma-Aldrich, A8674)
The test does not predict your exact glutathione response, but genetic markers in glutathione S-transferase (GST) and related pathways can support a more informed discussion about whether a standard single-dose protocol or a personalized, twice-daily approach aligns better with your genetic predispositions
